Poolbeg Pharma has successfully raised £4.715 million to fund innovative clinical trials, including POLB 001 and an oral GLP-1 programme, addressing critical medical needs...
Poolbeg Pharma plc (LON:POLB) announces a conditional fundraising aimed at raising £4.1 million to drive innovative pharmaceutical developments and address unmet medical needs...
Poolbeg Pharma Plc has released its audited results for 2024, highlighting significant advancements in cancer immunotherapy, including the promising POLB 001 therapy...
Poolbeg Pharma's POLB 001 is an innovative, orally-administered treatment aiming to combat severe influenza and cytokine release syndrome, revolutionising immunotherapy...
Severe influenza is a critical health challenge that demands innovative solutions. Learn how advanced technologies are transforming care for high-risk populations...
Discover how Poolbeg Pharma's POLB 001 is transforming CAR-T cell therapies, aiming to reduce cytokine release syndrome and enhance patient safety in cancer treatment...
As concerns over public health rise, understanding influenza's impact on healthcare evolves into a key opportunity for savvy investors in biotech and vaccine development...
Poolbeg Pharma is innovating in oncology with POLB 001, a promising p38 MAP kinase inhibitor targeting Cytokine Release Syndrome, a critical complication in cancer therapies...
Poolbeg Pharma's CEO, Jeremy Skillington, will present at major industry conferences in March and April 2025, showcasing innovative therapies and advancements...
Poolbeg Pharma (LON:POLB) secures a crucial patent for POLB 001 in South Korea, enhancing its portfolio for treating severe influenza and other conditions...
HOOKIPA Pharma and Poolbeg Pharma enter talks for a potential acquisition aimed at developing next-generation immunotherapies for critical medical needs...
Poolbeg Pharma and HOOKIPA Pharma propose a new collaboration with Gilead Sciences set to invest up to $8.7495 million, pending further negotiations...
Los Consejos de Poolbeg Pharma y HOOKIPA Pharma anuncian el respaldo de Gilead para una posible oferta y la actualización de su recaudación de fondos...
Poolbeg Pharma and HOOKIPA Pharma confirm Gilead Sciences' support for participation in a $30 million+ private placement fundraise amid potential merger talks...
HOOKIPA Pharma and Poolbeg Pharma are exploring a potential all-share acquisition, aiming to create a powerful Nasdaq-listed biopharmaceutical entity...
Poolbeg Pharma secures US patent approval for POLB 001, enhancing its IP portfolio and advancing treatments for severe influenza and cytokine storms...
Poolbeg Pharma has successfully raised £4.715 million to fund innovative clinical trials, including POLB 001 and an oral GLP-1 programme, addressing critical medical needs...
Poolbeg Pharma plc (LON:POLB) announces a conditional fundraising aimed at raising £4.1 million to drive innovative pharmaceutical developments and address unmet medical needs...
Poolbeg Pharma Plc has released its audited results for 2024, highlighting significant advancements in cancer immunotherapy, including the promising POLB 001 therapy...
Poolbeg Pharma's POLB 001 is an innovative, orally-administered treatment aiming to combat severe influenza and cytokine release syndrome, revolutionising immunotherapy...
Severe influenza is a critical health challenge that demands innovative solutions. Learn how advanced technologies are transforming care for high-risk populations...
Discover how Poolbeg Pharma's POLB 001 is transforming CAR-T cell therapies, aiming to reduce cytokine release syndrome and enhance patient safety in cancer treatment...
As concerns over public health rise, understanding influenza's impact on healthcare evolves into a key opportunity for savvy investors in biotech and vaccine development...
Poolbeg Pharma is innovating in oncology with POLB 001, a promising p38 MAP kinase inhibitor targeting Cytokine Release Syndrome, a critical complication in cancer therapies...
Poolbeg Pharma's CEO, Jeremy Skillington, will present at major industry conferences in March and April 2025, showcasing innovative therapies and advancements...
Poolbeg Pharma (LON:POLB) secures a crucial patent for POLB 001 in South Korea, enhancing its portfolio for treating severe influenza and other conditions...
HOOKIPA Pharma and Poolbeg Pharma enter talks for a potential acquisition aimed at developing next-generation immunotherapies for critical medical needs...
Poolbeg Pharma and HOOKIPA Pharma propose a new collaboration with Gilead Sciences set to invest up to $8.7495 million, pending further negotiations...
Los Consejos de Poolbeg Pharma y HOOKIPA Pharma anuncian el respaldo de Gilead para una posible oferta y la actualización de su recaudación de fondos...
Poolbeg Pharma and HOOKIPA Pharma confirm Gilead Sciences' support for participation in a $30 million+ private placement fundraise amid potential merger talks...
HOOKIPA Pharma and Poolbeg Pharma are exploring a potential all-share acquisition, aiming to create a powerful Nasdaq-listed biopharmaceutical entity...
Poolbeg Pharma secures US patent approval for POLB 001, enhancing its IP portfolio and advancing treatments for severe influenza and cytokine storms...
